Welcome to our dedicated page for Heartbeam news (Ticker: BEAT), a resource for investors and traders seeking the latest updates and insights on Heartbeam stock.
HeartBeam, Inc. develops medical technology for ambulatory cardiac monitoring, centered on a patented cable-free 3D ECG platform that captures signals from three non-coplanar dimensions and synthesizes a 12-lead ECG. News commonly covers the FDA-cleared HeartBeam System for arrhythmia assessment, limited commercial launch activity, preventive cardiology and concierge practice deployments, AI-ECG collaboration, and development of on-demand patch and heart attack detection initiatives.
Corporate updates also include financial results and common-stock financing used to support commercialization, product development, AI capabilities, working capital, and general corporate purposes.
HeartBeam, a medical technology company specializing in cardiac care, announced its addition to the Russell Microcap® Index. This inclusion is effective post-market close on June 28, 2024, following the FTSE Russell’s annual reconstitution, which ranks the 4,000 largest US stocks by market capitalization as of April 30. Being part of the Russell Microcap® Index, which lists the smallest 1,000 securities in the Russell 2000® Index plus the next 1,000 smallest eligible securities, provides HeartBeam with enhanced visibility and potential accessibility to $10.5 trillion in assets benchmarked against these indexes. The Russell indexes serve as key benchmarks for investment managers and institutional investors.
Epitel, a pioneer in AI-powered brain health solutions, has announced the appointment of Ken Nelson to its Board of Directors. Nelson, an expert in digital health and remote patient monitoring, brings over 20 years of experience to Epitel. He has held key positions in leading companies such as BioTelemetry, iRhythm, and Bardy Diagnostics, with notable achievements including BioTelemetry's $2.8 billion acquisition by Philips and Bardy Diagnostics' $450 million acquisition by HillRom/Baxter. As Epitel strives to revolutionize brain monitoring with AI and wearable EEG technology, Nelson's strategic insight is expected to drive the company's growth and commercial success. He currently holds influential positions in several MedTech startups and advisory boards.
HeartBeam (NASDAQ: BEAT) announced new study data showing that its AI algorithm combined with vectorcardiography (VCG) outperformed expert cardiologists in detecting atrial flutter, a common arrhythmia. The study, presented at the Heart Rhythm Society annual meeting, involved 173 VCGs, single-lead ECGs, and 12-lead ECGs. Key findings revealed a 40% improvement in detection sensitivity compared to single-lead ECGs reviewed by cardiologists and a 6% improvement over 12-lead ECGs. HeartBeam's core technology captures heart signals in three projections, aiming for a more personalized cardiac care approach. Their AIMIGo™ device, for patient use, is under FDA review.
HeartBeam, Inc. (NASDAQ: BEAT) has won the 'Best New ECG Technology Solution' award in the 8th annual MedTech Breakthrough Awards for their HeartBeam AIMIGo™ device. The AIMIGo™ device is a credit card-sized tool that allows for remote evaluation of cardiac symptoms, capturing heart signals in three projections and synthesizing them into a 12-lead ECG. The device is currently under FDA review and aims to provide a personalized approach to cardiac care outside of medical facilities.
HeartBeam, Inc. (NASDAQ: BEAT) reported positive results for its AIMIGo™ 3D VECG system, showcasing progress in clinical and regulatory milestones. The company anticipates FDA clearance by Q2 2024 for the AIMIGo system and plans for a launch by 2024 end. The VALID-ECG pivotal study for the 12-Lead Synthesis Software submission is underway, aiming to demonstrate similarity with a standard 12-lead ECG. HeartBeam AI showed improved performance in detecting arrhythmias, supported by new patents and positive data presented at EHRA conference. Cash and cash equivalents stood at approximately $12.6 million as of March 31, 2024, enabling future clinical and regulatory milestones.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.